作者
Per-Henrik D Edqvist, Jutta Huvila, Björn Forsström, Lauri Talve, Olli Carpén, Helga B Salvesen, Camilla Krakstad, Seija Grénman, Henrik Johannesson, Oscar Ljungqvist, Mathias Uhlén, Fredrik Pontén, Annika Auranen
发表日期
2015/6/1
期刊
Gynecologic oncology
卷号
137
期号
3
页码范围
529-537
出版商
Academic Press
简介
Objective
For endometrial carcinoma, prognostic stratification methods do not satisfactorily identify patients with adverse outcome. Currently, histology, tumor grade and stage are used to tailoring surgical treatment and to determine the need for adjuvant treatment. Low-risk patients are not considered to require adjuvant therapy or staging lymphadenectomy. For patients with intermediate or high risk, some guidelines recommend tailoring adjuvant treatment according to additional negative prognostic factors. Our objective was to evaluate the biomarker potential of the ASRGL1 protein in endometrial carcinoma.
Methods
Using The Human Protein Atlas (www.proteinatlas.org), the l-asparaginase (ASRGL1) protein was identified as an endometrial carcinoma biomarker candidate. ASRGL1 expression was immunohistochemically evaluated with an extensively validated antibody on two independent endometrial …
学术搜索中的文章
PHD Edqvist, J Huvila, B Forsström, L Talve, O Carpén… - Gynecologic oncology, 2015